Clinical trial
A Pilot Study of Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated Grade 3 Neuroendocrine Carcinomas
NCT03278405 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated Grade 3 Neuroendocrine Carcinomas
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 15, 2017
- Completion date
- March 12, 2020
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
neuroendocrine carcinoma